NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/02/2026
Voltar para busca
Dado oficial do USPTO
GENESISCARE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: Estados Unidos
Snapshot rápido
GENESISCARE
ST13
US500000079241451Classe
36, 41, 42, 44
Pedido
79241451
Registro
5876298
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
41
Atualização mais recente
03/03/2026
Tipo de marca
Verbal
Classes Nice
36, 41, 42, 44
Data de depósito
25/07/2018
Data de registro
08/10/2019
Data de expiração
-
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
12/02/2026
Última transação
03/03/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
708
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
Waterlooville, Hampshire, GB
Examinador
STINSON, JENNIFER ELLE
Localização atual
Historical data usage
Titulares e representantes
Titulares
Genesis Specialist Care Holding UK Limited
Representantes
Andrew S. Ehard Merchant & Gould P.C.
Classificação técnica
Classes Nice
Classe 36Classe 41Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 36
Charitable foundation servicesproviding financial assistance to organisationsprogramsservices of others for medical and healthcare research and to individuals of need for healthcare and the treatment of medical conditionsall the forgoing for the diagnosis and treatment of cancer and cardiac conditions; providing charitable fund raising activities the funds of which are to be used for providing financial assistance for organisationsprogramsservices of others for medical and healthcare research and to individuals of need for healthcare and the treatment of medical conditionsall the foregoing for the diagnosis and treatment of cancer and cardiac conditions
Classe 41
Providing continuing medical education courses and medical training services in the field of cancer and cardiac care
Classe 42
Medical research in the field of cancer and cardiac care
Classe 44
Medical servicesmedical advisoryexamination and treatment servicesmedical analysis services for the diagnosis of cancermedical diagnostic services in the nature of testing and analysis for the diagnosis of cancermedical care services and medical clinics specializing in the diagnosis and treatment of cancer and cardiac conditions ; medical information and consultancy services; all the foregoing in the field of cancer and cardiac conditions
Publicações
Histórico de despachos e eventos da marca no USPTO.
41 publicações encontradas
NA75
NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
12/02/2026
C75P
REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
12/02/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/02/2026
ES75
TEAS SECTION 71 & 15 RECEIVED
06/10/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
14/08/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
21/02/2020
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/02/2020
FIMP
FINAL DISPOSITION PROCESSED
01/02/2020
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
08/01/2020
R.PR
REGISTERED-PRINCIPAL REGISTER
08/10/2019
GPNX
NOTIFICATION PROCESSED BY IB
02/08/2019
PUBO
PUBLISHED FOR OPPOSITION
23/07/2019
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
17/07/2019
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
17/07/2019
NPUB
NOTICE OF PUBLICATION
03/07/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
19/06/2019
CNEA
EXAMINERS AMENDMENT MAILED
19/06/2019
XAEC
EXAMINER'S AMENDMENT ENTERED
18/06/2019
CNEA
EXAMINERS AMENDMENT -WRITTEN
18/06/2019
CNFR
FINAL REFUSAL MAILED
18/06/2019
CNFR
FINAL REFUSAL WRITTEN
17/06/2019
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/05/2019
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
20/05/2019
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
20/05/2019
ALIE
ASSIGNED TO LIE
16/05/2019
ALIE
ASSIGNED TO LIE
07/05/2019
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
30/04/2019
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
30/04/2019
RFNT
REFUSAL PROCESSED BY IB
05/01/2019
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
14/12/2018
RFRR
REFUSAL PROCESSED BY MPU
14/12/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
30/11/2018
CNRT
NON-FINAL ACTION WRITTEN
29/11/2018
RFWR
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
28/11/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/11/2018
CNRT
NON-FINAL ACTION WRITTEN
13/11/2018
DOCK
ASSIGNED TO EXAMINER
12/11/2018
MAFR
APPLICATION FILING RECEIPT MAILED
05/10/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
01/10/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
27/09/2018
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace GENESISCARE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.